avella specialty market access presenation - mobile technology
Post on 07-May-2015
264 Views
Preview:
DESCRIPTION
TRANSCRIPT
Amplifying the High-Touch of Specialty Pharmacy through Mobile and Web-Based Tools
Rebecca M. Shanahan, Esq.CEO of Avella Specialty Pharmacy
July 29, 2014
2 | Confidential and proprietary
Agenda
• Examine the shift toward digital — evolving customer demands and engagement opportunities
• Delve into an Avella Specialty Pharmacy case study highlighting mobile and web-based tools
• Identify industry best practices and early adopter examples
Does Mobile Technology Matter?That mHealth Data Trends
71% 62% 59%
71% of nurses are using smartphones at work
62% of physicians are now using tablets, with over half of them using one at point-of-care
59% of patients in emerging markets use at least one mobile health app or service (compared with only 35% in the developed world).
Source: electronichealthreporter.com/mhealth-stats-mobile-apps-devices-and-solutions/
Does Mobile Technology Matter?Data Points
Source: www.greatcall.com/lp/is-mobile-healthcare-the-future-infographic.aspx
6 | Confidential and proprietary
Emerging TechnologiesHow to investigate and assess opportunities
• Cross-functional team assessment • Clinical, Operations, IT, Marketing, etc.
• No technology “one-trick ponies” • Customer-centric NOT Business-centric
• Strong user-interface / experience
• Vendor/partner trajectory (not just current state)
• Technology adoption (fad or future)• Beyond “proof of concept”
• Plenty of interesting technologies, but what actually works?
7 | Confidential and proprietary
“Responsive” WebsiteAddressing the Mobile Visitor
• Over 20% of Google searches are being performed on a mobile device.
• 61% of people have a better opinion of brands when they offer a good mobile experience on your website.
• 48% of users stated that when a site doesn't function on their mobile device it makes them feel that the company does not care for their business.
Source: Google's Think Insights on Mobile Report
Avella Mobile App
10 | Confidential and proprietary
Why an Avella App?Driving reasons to develop and promote mobile app
• Every prescription counts / every day delayed counts
• Lowered operational costs• Measureable ROI• Meet the expectations of traditional Rx
customers• Engage / empower / educate our patients• DELIGHT customers• Differentiation vs. competition
11 | Confidential and proprietaryMobile App
12 | Confidential and proprietary
App FunctionalityKey features available on the Avella app
• Prescription lookup
• Prescription refill
• Prescription status
• Transfer prescription
• Pharmacy lookup
• Contact Avella locations
• Store physician information
• Connect with Avella / provide feedback
13 | Confidential and proprietary
What Success Would Look Like
• Delighted customers (internal and external)
• Improved metrics for cohort of app users• Higher customer satisfaction• Increased refill rate• Improved health outcomes
• Doesn’t make a consultative process a transactional one.
• Doesn’t set false customer expectations
Digital Promotion TacticsMobile Locations Page | Email Campaigns
Offline Promotion TacticsIn-store Video Signage | Rack Cards | Patient Fax Notifications
16 | Confidential and proprietary
Dashboard
17 | Confidential and proprietary
Dashboard
5/10
/14
5/11
/14
5/12
/14
5/13
/14
5/14
/14
5/15
/14
5/16
/14
5/17
/14
5/18
/14
5/19
/14
5/20
/14
5/21
/14
5/22
/14
5/23
/14
5/24
/14
5/25
/14
5/26
/14
5/27
/14
5/28
/14
5/29
/14
5/30
/14
5/31
/14
6/1/
14
6/2/
14
6/3/
14
6/4/
14
6/5/
14
6/6/
14
6/7/
14
6/8/
14
6/9/
14
0
20
40
60
80
100
120
140
160
180
Rx by typing Rx by on phone Rx by SMS Total for the day
Text Message Program Case Study
19 | Confidential and proprietary
Text Messaging Program Case Study
Objective:• To assess the impact of bi-directional SMS
technology on patient adherence through measurement of refill rates in specialty population.
Hypothesis:• Bi-directional SMS technology will improve
patient and clinician engagement resulting in increased medication adherence.
20 | Confidential and proprietary
• Text messaging program• Daily reminders to take medication• Reminders for lab work • Educational tips, e.g. blood pressure
monitoring • Motivational messaging• Patient surveys
• Gather lab values
• Pharmacist intervention for any indication of non-compliance
• Clinician notified• Weekly emails to clinical staff
• Refill Reminders
Bi-Directional Text Messaging Program
21 | Confidential and proprietary
Text Messaging Program Case Study
• 29% increase in adherence for low compliant cohort
Group 1: Low compliant patients
Group 2: High compliant patients
Group 3: Treatment naïve patients
Significant impact on refill rates
GlowCaps® Case Study
23 | Confidential and proprietary
GlowCaps® Case Study
Objective:• Determine if cost savings and positive
health outcomes result from patient adoption of GlowCap® adherence tools.
Hypothesis:• Adoption of GlowCaps will increase patient
adherence, resulting in positive health incomes and reduced hospitalization and medical care costs.
24 | Confidential and proprietary
“A quick reminder from your friends at Avella: Don't
forget to take your <time of day> pill in your
GlowCap®.”
How Do GlowCaps® Remind Patients?
1. GlowCap® flashes orange at reminder time for the 1st hour
2. GlowCap® flashes orange and plays ringtone for the 2nd hour
3. Patient receives an automated phone call
25 | Confidential and proprietary
Our pilot program demonstrated a 50% increase in medication adherence at month 4 of therapy for Tasigna® patients using GlowCap (vs. control group).
26 | Confidential and proprietary
GlowCaps® Case Study
Oct. 11 Nov. 11 Dec. 11 Jan. 12
100.0%
82.6%89.5% 90.0%
100.0%
92.2%
80.4%
60.0%
Avella Tasigna Patient Adherence by GlowCap Use
(Oct'11-Jan'12)
GlowCap (n=23) No GlowCap (n=51)
27 | Confidential and proprietary
GlowCaps™ Case StudyResults
Gleevec treated GIST Patients:• Patients with > 90% adherence had fewer hospitalizations,
reduced inpatient length of stays and lower medical costs compared with patients with < 70% adherence.*
Length of stays: • 3.4 vs. 29.9 days
Mean total medical care costs*:• $15,088 vs. $39,743 (during 1st year follow-up)• $38,062 vs. $71,126 (throughout follow-up)
• GlowCap users demonstrated an increase in medication adherence vs. the control group.
*Halpern, R., Barghout, V., Zarotsky, V., Williams, D. (2009). Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. Journal of Clinical Outcomes Management, 16(5); 215-223.
28 | Confidential and proprietary Provider Portal
Other Novel Examples
Does Mobile Technology Matter?Data Points
Accredo“Plus C” Mobile App
JanssenPsoriasis Mobile App
BiogenMicro8 App
Briova“Briova Live”
34 | Confidential and proprietary
Visual IVR
Turns This Into This:
Source: http://www.visual-ivr.com/
Apple – Health KitPulling Disparate mHealth Data Together
WalgreensBalance Rewards for Healthy Choices
37 | Confidential and proprietary
What this Means to Specialty Pharmacy
• Focus on a tool that solves multiple challenges for your patients.
• Start with tools that help long-term patients (i.e. hemophilia, HIV)
• Invest in mobile solutions that improve:
• Brand differentiation• Patient satisfaction• Communication /
collaboration across healthcare continuum
• Patient adherence• Health outcomes• Healthcare costs
38 | Confidential and proprietary
Stay Connected
Rebecca M. Shanahan, Esq.CEO of Avella
linkedin.com/pub/rebecca-shanahan/7/100/262
rebecca.shanahan@avella.com
@AvellaRx
top related